Simplified Insulin Delivery Worn Like a Patch

V-Go is an easy-to-use, wearable insulin device that:

Provides glucose control without multiple daily injections
(MDI)₁
Releases a steady rate of rapid-acting^† insulin for basal control₂
Delivers prandial insulin at the click of a button₂

V-Go indicated for use in adult patients requiring insulin.
^†A U-100 fast- acting insulin should be used with V-Go. Humalog^® (insulin lispro [rDNA origin] injection) and NovoLog^® (insulin aspart [rDNA origin] injection) have been tested by Valeritas, Inc. and found to be safe for use in V-Go.

Humalog^® is a registered trademark of Eli Lilly and Company.

NovoLog^® is a registered trademark of Novo Nordisk A/S.

Control and compliance for your patients

V-Go delivers a continuous preset basal rate of insulin over 24 hours while providing discreet on-demand bolus insulin dosing at mealtimes with simple clicks₂
Easy-to-use wearable insulin device helps support adherence and improve glycemic control_1-6

PLAY VIDEO

An Expert’s Perspective: The Value of V-Go for Patients on MDI

Hear a Nurse Practitioner talk about how V-Go can help overcome the burdens of adherence to multiple daily injections, resulting in an increase in morale for her patients and better compliance.

PLAY VIDEO

References: 1. Lajara R, Fetchick DA, Morris DA, Nikkel C. Use of V-Go® insulin delivery device with sub-optimally controlled diabetes mellitus: a retrospective analysis from a large specialized diabetes system. Diabetes Ther. 2015;6(4):531-545. 2. Instructions for Patient Use. Valeritas Inc. 2018. 3. Kapitza C, et al. J Diabetes Sci Technol. 2008;2(1):40-46. 4. Grunberger G, et al. Poster presented at: American Association of Clinical Endocrinologists 23rd Annual Scientific and Clinical Congress; May 14-18, 2014; Las Vegas, NV. Abstract 224. 5. Omer A, et al. Poster presented at: American Diabetes Association 73rd Scientific Sessions; June 21-25, 2013; Chicago, IL. Abstract 980-P. 6. Rosenfeld CR, et al. Endocr Pract. 2012;18(5):660-667.

Important Risk Information

If regular adjustments or modifications to the basal rate of insulin are required in a 24-hour period, or if the amount of insulin used at meals requires adjustments of less than 2-Unit increments, use of the V-Go Wearable Insulin Delivery Device may result in hypoglycemia. The following conditions may occur during insulin therapy with V-Go: hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose). Other adverse reactions associated with V-Go use include skin irritation from the adhesive pad or infections at the infusion site. V-Go should be removed before any magnetic resonance imaging (MRI) testing.